Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis
The European Commission has approved Kesimpta® (ofatumumab) for the treatment…
Ofatumumab, the new potential first-choice treatment for Relapsing forms of Multiple Sclerosis
Novartis has announced that both the US Food and Drug Administration (FDA) and…
First generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS)
The U.S. Food and Drug Administration has approved three applications for first…